<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="antiviral immune responses in the respiratory and intestinal tracts to" exact="infection" post="with severe coronaviruses that have caused epidemic diseases in"/>
 <result pre="protecting tissue damage and inflammation at the early phase of" exact="infection" post="[5]. However, recent studies revealed that excessive expression of"/>
 <result pre="disrupt the repair of lung epithelial tissue during respiratory viral" exact="infection" post="[6,7,8]. Indeed, coronaviruses are known to efficiently circumvent the"/>
 <result pre="can barely be detected during the early phase of coronavirus" exact="infection" post="[9,10]. Compared with SARS and MERS, COVID-19 patients have"/>
 <result pre="the S protein for membrane fusion in SARS-CoV and SARS-CoV-2" exact="infection" post="[30]. Notably, ACE2 and TMPRSS2 are also highly expressed"/>
 <result pre="that the digestive system is a potential route for SARS-CoV-2" exact="infection" post="[33,34]. 3. Antiviral Immune Responses to Coronavirus Infection The"/>
 <result pre="could interact with different sialic acid residues to modulate the" exact="infection" post="efficiency [40,41]. Moreover, the number of goblet cells was"/>
 <result pre="in the small intestine during the early phase of PEDV" exact="infection" post="[42], but studies focused on the interplay between different"/>
 <result pre="virus by pattern-recognition receptors (PRRs). The PRRs involved in the" exact="detection" post="of viral pathogens mainly include toll-like receptors (TLRs), retinoic"/>
 <result pre="single-stranded RNA (ssRNA), and glycoproteins, can be recognized during viral" exact="infection" post="and replication via TLRs and RLRs, resulting in the"/>
 <result pre="induces an effective host cell-intrinsic antiviral defense against lethal SARS-CoV" exact="infection" post="[50]. In contrast, TLRs 7 and 8 of plasmacytoid"/>
 <result pre="adaptor protein myeloid differentiation factor 88 (MyD88) during the viral" exact="infection" post="[51]. A previous study indicated that pDCs control the"/>
 <result pre="response [53]. Nevertheless, whether pDCs are essential for controlling viral" exact="infection" post="still needs to be tested in SARS-CoV-2 patients. Moreover,"/>
 <result pre="via the activation of the transcriptional factor IRF3 [57]. Meanwhile," exact="infection" post="with MHV activates MDA5 signaling, resulting in decreased levels"/>
 <result pre="effectively reduces the severity of MHV-induced pathogenesis [58]. Nevertheless, SARS-CoV" exact="infection" post="causes temporal and spatial activation of the transcriptional factor"/>
 <result pre="chemokines, and ISGs, which protect the host cells from viral" exact="infection" post="during the early phase. However, patients with severe disease"/>
 <result pre="recommended as potential therapeutic drugs to prevent and treat SARS-CoV-2" exact="infection" post="[70,71,72]. Notably, excessive and prolonged IFN expression might lead"/>
 <result pre="might lead to deleterious proinflammatory responses and may aggravate viral" exact="infection" post="by disrupting the lung epithelial barrier [7,8]. Thus, the"/>
 <result pre="in clinical practice against viral infection. 3.3.2. Proinflammatory Cytokines SARS-CoV" exact="infection" post="induces upregulation of proinflammatory cytokines/chemokines, such as interleukin (IL)-1Î²,"/>
 <result pre="of the recruitment of neutrophils and monocytes in controlling viral" exact="infection" post="[68]. 3.3.3. Interferon-Stimulated Genes (ISGs) IFNs activate the kinases"/>
 <result pre="surrounding uninfected cells [56,76]. This state can efficiently inhibit viral" exact="infection" post="and replication, and it also simultaneously induces priming of"/>
 <result pre="has been detected at the very early phase of SARS-CoV-2" exact="infection" post="after symptom onset [83], suggesting that the novel emerging"/>
 <result pre="the virus in breaking through the mucosal barrier and avoiding" exact="detection" post="by the PRRs on the cellular membrane of the"/>
 <result pre="is important to study the presence of ROs during coronavirus" exact="infection" post="in hosts. In addition, how the RNA intermediates are"/>
 <result pre="3CLpro is used for cleaving cellular substrates to promote viral" exact="infection" post="and inhibit the innate immune response through cleavage of"/>
 <result pre="resulting in attenuation of the innate immune response to virus" exact="infection" post="[108,109]. PDCoV nsp5 suppresses IFN expression via the cleavage"/>
 <result pre="thus, this proteinase is an ideal drug target for the" exact="treatment" post="of diseases caused by coronavirus infection [113,114]. 4.3.4. Modification"/>
 <result pre="drug target for the treatment of diseases caused by coronavirus" exact="infection" post="[113,114]. 4.3.4. Modification of the 5â€²-Cap Structure to Circumvent"/>
 <result pre="been shown to have an inhibitory effect on controlling viral" exact="infection" post="and replication in patients with COVID-19 [123]. Potential drugs"/>
 <result pre="inflammatory response to SARS-CoV-2, immune-based therapy is recommended for the" exact="treatment" post="of moderate to severe cases of COVID-19 [123]. Immunomodulatory"/>
 <result pre="[123,125,126]. In clinical trials, combination therapies are used for the" exact="treatment" post="of COVID-19. For instance, patients treated with a triple"/>
 <result pre="A summary of the action of these agents against SARS-CoV-2" exact="infection" post="is shown in Table 1. Besides the pharmacologic interventions,"/>
 <result pre="can delay IFN production during the early phase of viral" exact="infection" post="and induce hyperactive inflammatory responses in the advanced stages,"/>
 <result pre="new model for studying enteric coronavirus porcine epidemic diarrhea virus" exact="infection" post="and the host innate responseJ. Virol.201993e01682-1810.1128/JVI.01682-1830541861 11.CaoX.COVID-19: Immunopathology and"/>
 <result pre="porcine deltacoronavirus associated with diarrhoea in swine in China: Identification," exact="prevalence" post="and full-length genome sequence analysisTransbound Emerg. Dis.20156257558010.1111/tbed.1239926250097 24.MilletJ.K.WhittakerG.R.Host cell"/>
 <result pre="and tropismJ. Virol.201084113591137310.1128/JVI.00804-1020702616 49.KhanolkarA.HartwigS.M.HaagB.A.MeyerholzD.K.HartyJ.T.VargaS.M.TLR4-deficiency increases disease and mortality after MHV-1" exact="infection" post="in susceptible C3H miceJ. Virol.2009838946895610.1128/JVI.01857-0819553337 50.ToturaA.L.WhitmoreA.AgnihothramS.SchaferA.KatzeM.G.HeiseM.T.BaricR.S.Toll-like receptor 3 signaling"/>
 <result pre="in vivo during a viral infectionEMBO J.201837e9883610.15252/embj.20179883630131424 52.Cervantes-BarraganL.ZustR.WeberF.SpiegelM.LangK.S.AkiraS.ThielV.LudewigB.Control of coronavirus" exact="infection" post="through plasmacytoid dendritic-cell-derived type I interferonBlood20071091131113710.1182/blood-2006-05-02377016985170 53.Moreno-EutimioM.A.Lopez-MaciasC.Pastelin-PalaciosR.Bioinformatic analysis and"/>
 <result pre="SARS-CoV-2, SARS-CoV, and MERS-CoV genomesMicrobes Infect.20202222622910.1016/j.micinf.2020.04.00932361001 54.CaoL.GeX.GaoY.RenY.RenX.LiG.Porcine epidemic diarrhea virus" exact="infection" post="induces NF-kappaB activation through the TLR2, TLR3 and TLR9"/>
 <result pre="in porcine intestinal epithelial cellsJ. Gen. Virol.2015961757176710.1099/vir.0.00013325814121 55.ChenS.LuoG.YangZ.LinS.ChenS.WangS.GorayaM.U.ChiX.ZengX.ChenJ.L.Avian Tembusu virus" exact="infection" post="effectively triggers host innate immune response through MDA5 and"/>
 <result pre="and MDA5J. Virol.2010846472648210.1128/JVI.00016-1020427526 58.ZalingerZ.B.ElliottR.RoseK.M.WeissS.R.MDA5 is critical to host defense during" exact="infection" post="with murine coronavirusJ. Virol.201589123301234010.1128/JVI.01470-1526423942 59.YoshikawaT.HillT.E.YoshikawaN.PopovV.L.GalindoC.L.GarnerH.R.PetersC.J.TsengC.T.Dynamic innate immune responses of"/>
 <result pre="antagonism of interferonCurr. Opin. Virol.2012226427510.1016/j.coviro.2012.04.00422572391 62.ZhouJ.H.WangY.N.ChangQ.Y.MaP.HuY.CaoX.Type III interferons in viral" exact="infection" post="and antiviral immunityCell Physiol. Biochem.20185117318510.1159/00049517230439714 63.CaiB.BaiQ.ChiX.GorayaM.U.WangL.WangS.ChenB.ChenJ.L.Infection with classical swine"/>
 <result pre="molecular level to therapeutic effectsInt. Rev. Cell Mol. Biol.201632634337227572132 72.ZhouQ.ChenV.ShannonC.P.WeiX.-S.XiangX.WangX.WangZ.-H.TebbuttS.J.KollmannT.R.FishE.N.Interferon-Î±2b" exact="treatment" post="for COVID-19Front. Immunol.202011106110.3389/fimmu.2020.0106132574262 73.LiC.K.-f.XuX.Host immune responses to SARS coronavirus"/>
 <result pre="COVID-19Nat. Med.20202645345510.1038/s41591-020-0819-232284614 76.RaiK.R.ChenB.ZhaoZ.ChenY.HuJ.LiuS.MaaroufM.LiY.XiaoM.LiaoY.et al.Robust expression of p27Kip1 induced by viral" exact="infection" post="is critical for antiviral innate immunityCell Microbiol.2020e1324210.1111/cmi.1324232596986 77.PerngY.C.LenschowD.J.ISG15 in"/>
 <result pre="al.Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the" exact="treatment" post="of patients admitted to hospital with COVID-19: An open-label,"/>
 <result pre="25 August 2020) 130.VankadariN.Arbidol: A potential antiviral drug for the" exact="treatment" post="of SARS-CoV-2 by blocking trimerization of the spike glycoproteinInt."/>
 <result pre="J. Antimicrob. Agents20205610599810.1016/j.ijantimicag.2020.10599832360231 131.HoffmannM.SchroederS.Kleine-WeberH.MullerM.A.DrostenC.PohlmannS.Nafamostat mesylate blocks activation of SARS-CoV-2: New" exact="treatment" post="option for COVID-19Antimicrob. Agents Chemother.202064e00754-2010.1128/AAC.00754-2032312781 132.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and chloroquine effectively"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov.2020610.1038/s41421-020-0156-0 134.SchoergenhoferC.JilmaB.StimpflT.KarolyiM.ZoufalyA.Pharmacokinetics of lopinavir and ritonavir in"/>
 <result pre="signaling in human leukocyte subpopulationsArthritis Res. Ther.20192118310.1186/s13075-019-1964-131375130 139.CaoY.WeiJ.ZouL.JiangT.WangG.ChenL.HuangL.MengF.HuangL.WangN.et al.Ruxolitinib in" exact="treatment" post="of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind,"/>
 <result pre="on the epithelial surface is the first barrier against human" exact="infection" post="by coronaviruses, such as SARS-CoV, MERS-CoV, and the novel"/>
 <result pre="1Table 1 Potential antiviral and anti-inflammatory agents under evaluation for" exact="treatment" post="of COVID-19. Classification Drug Name Mechanism of Action Ref."/>
 <result pre="via inhibition of AKK1 that may prevent viral entry and" exact="infection" post="Inhibition of IL-6 induced STAT3 phosphorylation [138] Ruxolitinib JAK"/>
 <result pre="via inhibition of AKK1 that may prevent viral entry and" exact="infection" post="Inhibition of IL-6 through JAK1/JAK2 pathway [139]"/>
</results>
